LataMed AI Corp. (OTC: LMED), a healthcare technology company specializing in digital health and artificial intelligence solutions for Latin America, has announced a new collaboration with Droguerias Lala C.A. to develop artificial intelligence-supported and automated software tools for pharmaceutical and laboratory operations. The agreement, made through its Venezuelan subsidiary LATAMEDAI VE, aims to create customized technology to support workflows in pharmaceutical research, laboratory testing, quality control, documentation, operational coordination, and data analysis.
The proposed technology is expected to incorporate software tools designed to organize and analyze information generated during pharmaceutical development and laboratory activities. Planned functionality may include workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytical tools intended to help qualified personnel identify potential inconsistencies or operational issues at an earlier stage. The collaboration will begin by identifying specific workflows to be addressed, defining technical and operational requirements, and establishing a phased development and testing process, along with confidentiality and data-management procedures.
The parties will evaluate whether the technology can assist qualified personnel with the organization and review of information associated with pharmaceutical formulas, laboratory results, quality standards, testing procedures, and applicable approval processes. Any such functionality would be designed as a decision-support and workflow-management resource and would not independently approve pharmaceutical formulas, laboratory results, medical products, or regulatory submissions. The agreement emphasizes that all pharmaceutical, scientific, laboratory, or quality-control determinations remain the responsibility of appropriately qualified professionals and regulatory authorities, and the technology would not replace independent professional judgment.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: “This agreement represents an opportunity to apply our artificial intelligence and automation capabilities within complex pharmaceutical and laboratory environments. Our objective is to work with DROGUERIAS LALA C.A. to develop responsible technology that supports data analysis, documentation, testing coordination, quality-control processes, and other operational requirements while preserving appropriate professional oversight.”
The collaboration could expand LataMed AI’s technology into enterprise pharmaceutical and laboratory applications beyond its patient-facing telemedicine services. It aligns with the company’s broader strategy of developing digital infrastructure and AI-supported tools for healthcare providers, pharmacies, laboratories, institutions, and other participants in the healthcare ecosystem. If successfully developed and implemented, the technology might provide a framework adaptable for other organizations in Venezuela and Latin America, subject to separate agreements, successful development, operational readiness, and regulatory requirements.
The agreement sets the framework for development and evaluation but does not guarantee implementation schedules, commercial deployment, cost reductions, scientific or regulatory outcomes, revenue, or expansion to additional organizations. The company will provide further information as development progresses. For more information, visit https://latamed.ai or review SEC filings at www.sec.gov.
